Editorial team
ioQuanta Research Desk
-
Evidence date ·What blood DNA and tumor cells could reveal during lung cancer immunotherapy
Review or Meta-AnalysisTracked over timeA 2021 review explains why testing tumor tissue for PD-L1 cannot predict every immunotherapy response and how repeated blood samples might track tumor changes.
-
Evidence date ·How a tumor encounter may shape an engineered T cell’s future
Review or Meta-AnalysisTracked over timeAn engineered T cell’s first division after meeting a tumor may help form memory cells that can respond if cancer returns, a 2026 review suggests.
-
Evidence date ·How can starting blood cells shape the staying power of engineered cancer fighters?
Peer-Reviewed PaperTracked over timeA 2023 overview links CAR T cell memory to treatment efficacy and examines starting-cell quality, manufacturing, and drug combinations as possible ways to sustain cell function.
-
Evidence date ·Why killing cancer cells may not be enough for CAR T cells
Review or Meta-AnalysisTracked over timeA 2021 review explains why CAR T cells need more than killing power: they must reach solid tumors, replenish active cells and keep working there.
-
Evidence date ·What might targeted drugs add to radiation for children?
Review or Meta-AnalysisA 2021 review finds few early tests of targeted drugs alongside radiation in childhood cancer and explains why reliable experiments matter for clinical trials.
-
Evidence date ·Why rare cancers beyond the lung borrow a lung cancer treatment approach
Review or Meta-AnalysisA 2021 review explains why rare neuroendocrine cancers receive lung cancer treatment and how shared biology points to new drug targets.
-
Evidence date ·Why one glioma signal may affect blood vessels and immune defenses
Review or Meta-AnalysisA 2021 review links VEGF, a blood-vessel growth signal, to immune suppression in high-grade glioma and discusses why pairing treatments is being considered.
-
Evidence date ·Why might standard rectal cancer treatment change the chances for immunotherapy?
Review or Meta-AnalysisRadiation and chemotherapy may expose rectal tumors to immune attack while also restraining T cells. Could immunotherapy tip the balance?
-
Evidence date ·Immune cells may not tell the whole story in breast tumors
Peer-Reviewed PaperTwo possible immune brakes tracked with stem-like tumor patterns and were more highly expressed in an immune-rich breast cancer subtype linked to poor survival.
-
Evidence date ·A biopsy found reactive tissue in one new scan spot during lymphoma treatment
Review or Meta-AnalysisWhen new scan spots appeared during lymphoma treatment, a biopsy found reactive tissue in one. The patient remained in remission at 33 months.